EGFR and non-small cell lung carcinoma: The introduction of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) into the treatment paradigm of NSCLC harboring EGFR mutations dramatically improved clinical outcomes.